Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: Potential implications to L-DOPA long-term therapy of Parkinson's disease

British Journal of Pharmacology

Volumn 130, Issue 4, 2000, Pages 937-945

  Serra, Pier Andrea ^a   Esposito, Giovanni ^a   Enrico, Paolo ^a   Mura, Maria A ^a   Migheli, Rossana ^a   Delogu, M Rosaria ^a   Miele, Maddalena ^a   Desole, Maria S ^a   Grella, Giuseppe ^a   Miele, Egidio ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

Dopamine; Im vivo auto oxidation; L DOPA; L DOPA semiquinone; Manganese; Microdialysis; Rat striatum

Indexed keywords

ASCORBIC ACID; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; LEVODOPA; MANGANESE; REACTIVE OXYGEN METABOLITE; URIC ACID; XANTHINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOOXIDATION; CONTROLLED STUDY; CORPUS STRIATUM; DIALYSATE; DRUG OXIDATION; MALE; MICRODIALYSIS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

EID: 0034042511     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703379     Document Type: Article

References (41)

1. ANGLADE, P., VYAS, S., JAVOY-AGID, F., HERRERO, M.T., MICHEL, P.P., MARQUEZ, J., MOUATT-PRIGENT, A., RUBERG, M., HIRSCH, E.C. & AGID, Y. (1997). Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Hisiopathol., 12, 25-31.
2. BASMA, R.B., MORRIS, E.J., NIKLAS, W.J. & GELLER, M.H. (1995). L-DOPA cytotoxicity to PC12 cells in culture is via its autoxidation. J. Neurochem., 64, 825-832.
3. CHIUEH, C. (1994). Auto-oxidation of dopamine and formation of free radicals in vivo. In Monitoring Molecules in Neuroscience. ed Louilot, A., Durkin, T., Spampinato, U. & Cador, M. Universities of Bordeaux I and II, Bordeaux, pp. 127-128.
4. CHURCH, W.H. & WARD, V.L. (1994). Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine autooxidation. Brain Res. Bull., 33, 419-425.
5. COHEN, A.M., ABERDROTH, R.E. & HOCHSTEIN, P. (1984). Inhibition of free radical-induced DNA damage by uric acid. FEBS Lett., 174, 147-150.
6. DESOLE, M.S., SCIOLA, L., DELOGU, M.R., SIRCANA, S., MIGHELI, R. & MIELE, E. (1997). Manganese and 1-methyl-4-(2′-ethylphenyl)-1,2,3,6-tetrahydro/pyridine-induced apoptosis in PC12 cells: role of oxidative stress. Neurochem. Int., 31, 169-176.
7. DONALDSON, J. (1987). The physiopathological significance of manganese in brain: its relation to schizophrenia and neurodegenerative disorders. Neurotoxicology, 8, 451-462.
8. ENRICO, P., ESPOSITO, G., MURA, M.A., MIGHELI, R., SERRA, P.A., DESOLE, M.S., MIELE, E., DE NATALE, G. & MIELE, M. (1997). Effects of allopurinol on striatal dopamine, ascorbate and uric acid during an acute morphine challenge: ex vivo and in vivo studies. Pharmacol Res., 35, 577-585.
9. FLORENCE, T.M. & STAUBER, J.L. (1989). Manganese catalysis of dopamine auto-oxidation. Sci. Total Environ., 78, 233-240.
10. HALLIWELL, B. (1992). Reactive oxygen species and the central nervous system. J. Neurochem., 59, 1609-1623.
11. HASTINGS, T.G., LEWIS, D.A. & ZIGMOND, M.J. (1996). Role of oxidative stress in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. U.S.A., 93, 1056-1061.
12. JELLINGER, K.A. (1999). The role of iron in neurodegeneration. Prospect for pharmacotherapy of Parkinson's disease. Drugs Aging, 14, 115-140.
13. JIMENEZ-JIMENEZ, F.J., MOLINA, J.A., AGUILAR, M.V., ARRIETA, F.J., JORGE-SANTAMARIA, A., CABRERA-VALDIVIA, F., AYUSO-PERALTA, L., RABASA, M., VAZQUEZ, A. & GARCIA-ALBEA, E. (1995). Serum and urinary manganese levels in patients with Parkinson's disease. Acta Neurol. Scand., 91, 317-320.
14. KEYER, K. & IMLAY, J.A. (1996). Superoxide accelerates DNA damage by elevating free-iron levels. Proc. Natl. Acad. Sci. U.S.A., 93, 13635-13640.
15. KLEGERIS, A., KORKINA, L.G. & GREENFELD, S.A. (1995). Autooxidation of dopamine: a comparison of luminescent and spectrophotometric detection in basic solutions. Free Rad. Biol. Med., 18, 215-222.
16. LAI, C.T. & YU, P.H. (1997). Dopamine and L-3,4-dihydroxyphenylalanine hydrochloride (L-DOPA)-induced cytotoxicity towards catecholaminergic neuroblastoma HS-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem. Pharmacol., 53, 363-372.
17. LAM, D.K.C. & DANIEL, P.M. (1986). The influx of ascorbic acid into the rat brain. Quart. J. Exp. Physiol., 71, 483-490.
18. MARSDEN, C.D. & PARKER, J.D. (1977). Success and problem of chronic levodopa therapy in Parkinson's disease. Lancet., 1, 345-349.
19. MIELE, M. & FILLENZ, M. (1996). In vivo determination of extracellular brain ascorbate. J. Neurosci. Meth., 69, 21-24.
20. MIELE, M., MURA, M.A., ENRICO, P., ESPOSITO, G., SERRA, P.A., MIGHELI, R., ZANGANI, D., MIELE, E. & DESOLE, M.S. (2000). On the mechanism of d-amphetamine-induced changes in glutamate, ascorbic acid and uric acid release in the striatutn of freely moving rats. Br. J. Pharmacol., 129, 582-588.
21. MIGHELI, R., GODANI, C., SCIOLA, L., DELOGU, M.R., SERRA, P.A., ZANGANI, D., DE NATALE, G., MIELE, E. & DESOLE, M.S. (1999). Enhancing effect of manganese on L-DOPA-induced apoptosis in PC12 cells: role of oxidative stress. J. Neurochem., 73, 1155-1163.
22. MOCHIZUKI, H., GOTO, K., MORI, H. & MIZUNO, Y. (1996). Histochemical detection of apoptosis in Parkinson's disease. J. Neural. Sci., 137, 120-123.
23. MORTON, D.B. & GRIFFITHS, P.H.M. (1985). Guidelines on the recognition of pain, distress and discomfort in experimental animals and a hypothesis for assessment. Vet. Rec., 116, 431-436.
24. PARENTI, M., FLAUTO, C., PARATI, E., VESCOVI, A. & GROPPETTI, A. (1986). Manganese neurotoxicity: effects of L-DOPA and pargyline treatments. Brain Res., 367, 8-13.
25. PARSONS, P.G. (1985). Modification of dopa toxicity in human tumour cells. Biochem. Pharmacol., 34, 1801-1807.
26. PAXINOS, G. & WATSON, C. (1986). Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego.
27. SARRE, S., VANDENEEDE, D., EBINGER, G. & MICHOTTE, Y. (1998). Biotransformation of L-DOPA to dopamine in the substantia nigra of freely moving rats: effect of dopamine receptor agonists and antagonists. J. Neurochem., 70, 1730-1739.
28. SEVANIAN, A., DAVIES, K.J.A. & HOCHSTEIN, P. (1991). Serum urate as an antioxidant for ascorbic acid. Amer. J. Clin. Nutr., 54, 29S-134S.
29. SHEN, X.M. & DRYHURST, G. (1998). Iron-and manganese-catalyzed auto-oxidation of dopamine in the presence of L-cysteine: possible insights into iron-and manganese-mediated dopaminergic neurotoxicity. Chem. Res. Toxicol., 11, 824-837.
30. SLOOT, W.N., KORF, J., KOSTER, J.F., DE WIT, L.E. & GRAMSBERGEN, J.B. (1996). Manganese-induced hydroxyl radical formation in rat striatum is not attenuated by dopamine depletion or iron chelator in vivo. Exper. Neurol., 138, 236-245.
31. SMITH, T.S., PARKER, Jr, W.D. & BENNETT, Jr, J.P. (1994). L-DOPA increases nigral production of hydroxyl radicals in vivo: potential L-DOPA toxicity? Neuroreport, 5, 1009-1011.
32. SPECTOR, R. (1982). Penetration of ascorbic acid from cerebrospinal fluid into brain. Exp. Neurol., 72, 645-653.
33. SPENCER, J.P., JENNER, P., DANIEL, S.E., LEES, A.J., MARSDEN, D.C. & HALLIWELL, B. (1998). Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanism of formation involving reactive oxygen species. J. Neurochem., 71, 2112-2122.
34. SPENCER, J.P., JENNER, P. & HALLIWELL, B. (1995). Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. Neuroreport, 6, 1480-1484.
35. TAKEDA, A., KODAMA, Y., ISIWATARI, S. & OKADA, S. (1998). Manganese transport in the neural circuit. Brain Res. Bull., 45, 149-152.
36. THE PARKINSON STUDY GROUP. (1993). Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. New Engl. J. Med., 328, 176-183.
37. VIEREGGE, P., HEINZOW, B., KORF, G., TEICHERT, H.M. & SCHLEIFENBAUN, P., MONSINGER, H.U. (1995). Long term exposure to manganese in rural well has no neurological effects. Can. J. Neurol. Sci., 22, 286-289.
38. WALKINSHAW, G. & WATERS, C.M. (1995). Induction of apoptosis in catechol/aminergic PC12 cells by L-DOPA. Implication for the treatment of Parkinson's disease. J. Clin. Invest., 95, 2458-2464.
39. ZETTERSTRÖM, T., SHARO, T. & UNGERSTEDT, U. (1986). Further evaluation of the mechanism by which amphetamine reduces striatal dopamine metabolism: a brain dialysis study. Eur. J. Pharmacol., 132, 1-9.
40. ZIV, I., MELAMED, E., NARDI, N., LURIA, D., ACHIRON, A., OFFEN, D. & BARZILAI, A. (1994). Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons - a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci. Lett., 170, 136-140.
41. ZIV, I., ZILKHA-FALB, R., OFFEN, D., SHIRVAN, A., BARZILAI, A. & MELAMED, E. (1997). Levodopa induces apoptosis in cultured neuronal cells: a possible accelerator of nigrostriatal degeneration in Parkinson's disease? Mov. Dis., 12, 17-23.